1. Allampallam K, Shetty V, Dar S, Hussaini S, Cartilidge J, Broderick E, Townsend W, Qawi H, Mazzoran L, Mahamood W, Mundle S, Reza S, Gundroo A, Yakoob L, Robinson L, Preisler H & Raza A. (1997) Elevated levels of serum tumor necrosis factor receptors in myelodysplastic syndromeBlood92, Abst. # 1743, 422a.
2. Allampallam K, Shetty V, Hussaini S, Mazzoran L, Zorat F, Huang R & Raza A (1999). Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes.Anticancer Research19,5323–5328.
3. Allampallam K, Shetty V, Broady Robinson L, Hussaini S., Broderick E, Mundle S, Reddy P, Dar S, Zaidi A, Nascimben F & Raza A (2000). The clinical and biological significance of apoptosis, macrophages and cytokines in 145 patients with myelodysplastic syndromes.Blood96,Abst # 1550, 359a.
4. Akoi I, Higashi K, Homori M, Chikazawa H & Ishikawa K. (1990). Responsiveness of bone marrow erythrrpoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rhEP) in vitro in aplastic anemia and myelodysplastic syndrome.American Journal Hematology35, 6–12.
5. Aul C, Arming M, Runde V & Schneider W (1991) Serum erythropoietin concentrations in patients with myelodysplastic syndromes.Leukemia Research15, 571–575.